WellPoint announced that effective immediately it will cover the Rotarix vaccine.
WellPoint announced that effective immediately it will cover the rotavirus vaccine, Rotarix, designed to prevent a virus which causes vomiting and diarrhea in infants and children. This decision to cover Rotarix, manufactured by GlaxoSmithKline, is based on formal recommendations announced by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). ACIP recommended that Rotarix be added to the list of recommended inoculations offered to infants. Rotarix is a liquid given in a two-dose series to infants six to 24 weeks old.